A Cure in Sight
๐Ÿ’™ PROMISING NEWS IN OCULAR MELANOMA RESEARCH! ๐Ÿ”ฌ Immunocore has announced encouraging results from a Phase 1/2 clinical

7 likes

๐Ÿ’™ PROMISING NEWS IN OCULAR MELANOMA RESEARCH!

๐Ÿ”ฌ Immunocore has announced encouraging results from a Phase 1/2 clinical trial evaluating the combination of brenetafusp and KIMMTRAKยฎ (tebentafusp) in patients with metastatic uveal melanoma. Among 17 patients who received the combination as their first treatment for metastatic disease: ๐Ÿ”น 70% estimated overall survival at two years ๐Ÿ”น 71% disease control rate ๐Ÿ”น 29% overall response rate Even more encouraging, Immunocore is planning a larger Phase 2/3 clinical trial, called DUET-UVEAL, to further evaluate this combination. While these findings are preliminary and more research is needed, they represent another hopeful step forward in the search for better treatment options for our community. At A Cure In Sight, we believe every advancement in research matters. ๐Ÿ’™ Rare Cancer. Resilient Hope. Revolutionary Research. #ACureInSight #OcularMelanoma #UvealMelanoma #CancerResearch #ClinicalTrials
See it on Instagram โ†—